BFM
BHVN

Boothbay Fund Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Boothbay Fund Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,552
Closed -$1.44M – 2839
2022
Q3 		$1.44M Buy
+9,552
New +$1.42M 0.04% 716
2022
Q2 		– Sell
-7,356
Closed -$872K – 2951
2022
Q1 		$872K Buy
+7,356
New +$917K 0.02% 978
2019
Q4 		– Sell
-10,142
Closed -$502K – 1131
2019
Q3 		$423K Sell
10,142
-9,218
-48% -$389K 0.04% 504
2019
Q2 		$848K Buy
+19,360
New +$1.09M 0.08% 298
2018
Q4 		– Sell
-14,665
Closed -$529K – 1059
2018
Q3 		$551K Buy
+14,665
New +$539K 0.05% 332
2018
Q2 		– Sell
-11,358
Closed -$293K – 1013
2018
Q1 		$293K Buy
+11,358
New +$340K 0.03% 479

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Boothbay Fund Management's BHVN Position: Q4 2022 in Review

Boothbay Fund Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 9,552 shares — an estimated $1.44M sold.

Boothbay Fund Management first reported a position in BHVN in Q1 2018 and held it in 6 quarters. The position peaked at $1.44M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Boothbay Fund Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 9,552 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.44M.
  • Boothbay Fund Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 6 quarters.
  • Boothbay Fund Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.44M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.